UNSPSC 51262603: Napamezole

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GK4C2D295B, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline but generally known as napamezole, which bears US NIH Compound Identifier 124655. European Medicines Agency schedules Napamezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09153MIG.

UNSPSC 51262603 Napamezole is a Commodity code that in recent state and local procurement activity encompasses naloxone (opioid-reversal medication) and related drug-deactivation or pharmacy-management systems serving public-health and emergency-response initiatives. The code appears in solicitations from health agencies and county health departments procuring naloxone units and associated equipment for community distribution, emergency medical preparedness, and pharmacy-benefit management. Issuing bodies include county health departments and state health-and-human-services commissions pursuing both direct product procurement and exploratory contracting models for pharmaceutical supply and fulfillment.

Recent activity centers in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the IFB required electronic submission by July 26, 2023, with all shipping and delivery costs included in vendor bids and a two-year term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment and therapeutic pharmacy initiatives, seeking information on vendors' experience with self-insured employer and government health-plan contracts and value-based or outcomes-based pricing models; this exploratory RFI precedes formal solicitation and indicates the state's intent to develop procurement specifications for subsequent RFP activity. Neither opportunity specifies explicit set-aside designations, though the Seminole County IFB requires E-Verify compliance and drug-free workplace certification.